Topiramate for smoking cessation
| Autor: | Yasser Khazaal, Jacques Cornuz, Daniele Fabio Zullino, Romain Bilancioni |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Topiramate
Adult Male medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment Smoking prevention Pilot Projects Smoking Prevention Fructose Internal medicine medicine Humans Receptors AMPA alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Addiction treatment media_common business.industry General Neuroscience General Medicine Abstinence Middle Aged Clinical trial Behavior Addictive Psychiatry and Mental health Anticonvulsant Neuroprotective Agents Neurology Anesthesia Smoking cessation Female Smoking Cessation Neurology (clinical) business medicine.drug |
| Zdroj: | Psychiatry and clinical neurosciences. 60(3) |
| ISSN: | 1323-1316 |
| Popis: | Due to its AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible-dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side-effects. Controlled trials are needed to confirm these preliminary observations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |